MAPK3 and cardiac hypertrophy: Finally, to further reveal the SG mechanism in the treatment of diabetes-induced cardiac hypertrophy, we need to investigate the effects of other DUSP isoforms on MAPKs other than ERK1/2 in vivo and in vitro.